维普中文期刊产品整合服务
116篇 您的检索式:作者名="Hsu MA"
    题名 作者 年代 出处 被引量
1YTHDF3 facilitates translation and decay of N6-methyladenosine-modified RNA显示文摘Hailing Shi Xiao Wang Zhike Lu Boxuan S Zhao Honghui Ma Phillip J HSU Chang Liu Chuan He 2017Cell Research2017,27,3:156
2Ythdc2 is an N^6-methyladenosine binding protein that regulates mammalian spermatogenesis显示文摘N 6-methyladenosine (m 6 一) 是在真核细胞的 mRNA 的最普通的内部修正。它动态地被安装并且搬迁,并且充当 mRNA 新陈代谢,包括干细胞 pluripotency 的调整生物过程,房间区别,和精力动态平衡的新层。m 6 A 被选择有约束力的蛋白质认出;YTHDF1 和 YTHDF3 在音乐会工作影响 m 6包含 A 的 mRNAs, YTHDF2 帮助 mRNA 腐烂,和 YTHDC1 影响它的目标的原子处理。YTHDC2 的生物功能, YTH 蛋白质家庭,的最后的成员仍然保持未知。我们报导 YTHDC2 有选择地绑 m 6 在它的一致主题的 A。YTHDC2 提高它的目标的翻译效率并且也减少他们的 mRNA 丰富。Ythdc2 猛烈老鼠是不肥沃的;男性们让显著地更小的睾丸和女性同窝出生的人与那些相比有显著地更小的卵巢。Ythdc2 猛烈老鼠的细菌房间不经过 zygotene 阶段发展,因此,当成熟分裂开始, Ythdc2 是在睾丸的 upregulated。因此, YTHDC2 是 m 6 在精子发生期间起关键作用的 A 绑定蛋白质。Phillip J Hsu Yunfei Zhu Honghui Ma Yueshuai Guo Xiaodan Shi Yuanyuan Liu Meijie Qi Zhike Lu Hailing Shi Jianying Wang Yiwei Cheng Guanzheng Luo Qing Dai Mingxi Liu Xuejiang Guo Jiahao Sha Bin Shen Chuan He 2017Cell Research2017,27,9:96
3Androgen Receptor Is a New Potential Therapeutic Target for the Treatment of Hepatocellular Carcinoma显示文摘Weng–Lung Ma Cheng–Lung Hsu Ming–Heng Wu Chun–Te Wu Cheng–Chia Wu Jiann–Jyh Lai Yuh–Shan Jou Chun–Wei Chen Shuyuan Yeh Chawnshang Chang 2008Gastroenterology2008,,3:2
4High-perfoimance carbon nanotube transparent conductive films by scablable dip coating显示文摘MIRRI F MA A W K HSU T T 2012Acs Nano2012,6,79:1
5Transcription factor nuclear factor-kappa B is activated in neurons after focal cerebral ischemia 显示文摘 Yin T Smalstig EB Hsu MA Panetta J Little S Clemeus J 2000J Cereb Blood Flow Metab2000,20,3:1
6Dictyoste- lium delicatum, a new record of dictyostelid cellular slime molds to Taiwan 显示文摘Hsu S L Fan Y C Ma M S Chou M H Yeh Z Y 2001Taiwania2001,44,:1
7Inhibition of platelet aggregation and expression of alpha granule membrane protein 140 and thromboxane b2 with pravastatin therapy for hypercholesterolemia显示文摘Ma LP Nie DN Hsu SX 2002J Assoc Acad Minor Phys2002,13,1:1
8Inhibition of platelet aggregation and expression of alpha gramule membrane protein 140 and thromboxane B2 with pravastatin therapy for hypercholesterolemia显示文摘Ma LP Nie DN Hsu SX 2002J Assoc Acad Minor Phys2002,13,1:1
9p38 mitogen-activated protein kinase is involved in Fas ligand expression 显示文摘Hsu SC Gavrilin MA Tsai MH 1999J Biol Chem1999,274,25:1
10Legionella prevalence in wastewater treatment plants of Taiwan显示文摘Huang S W Hsu B M Ma P H 2009Water Science and TechnOlogy2009,60,5:1
11Levels of PCDD/Fs in ambient air and soll in the vicinity of a municipal solid waste incinerator in Hsinchu显示文摘Cheng P S Hsu M S Ma E el al 2003Chemosphere2003,52,:1
12Consensus for sclerotherapy显示文摘Weiss MA Hsu JT Neuhaus I 2014Dermatol Surg2014,40,:1
13Androgen receptor promotes hepatitis B virus-induced hepatocarcinogenesis through modulation of hepatitis B virus RNA transcription显示文摘Wu MH Ma WL Hsu CL 2010Sci Transl Med2010,2,32:1
14The effective-ness of multimedia learning education programs onknowledge, anxiety and pressure garment compliance inpatients undergoing burns rehabilitation in Taiwan: anexperimental study 显示文摘Shu-Fen Lo Mark Hayter Ma Hsu 2010J Clin Nurs2010,19,1:1
15Tranexamic acid for intracerebral haemorrhage within 2 hours of onset: protocol of a phase Ⅱ randomised placebo-controlled double-blind multicentre trial显示文摘Rationale Haematoma growth is common early after intracerebral haemorrhage(ICH),and is a key determinant of outcome.Tranexamic acid,a widely available antifibrinolytic agent with an excellent safety profile,may reduce haematoma growth.Methods and design Stopping intracerebral haemorrhage with tranexamic acid for hyperacute onset presentation including mobile stroke units(STOP-MSU)is a phase Ⅱ double-blind,randomised,placebo-controlled,multicentre,international investigator-led clinical trial,conducted within the estimand statistical framework.Hypothesis In patients with spontaneous ICH,treatment with tranexamic acid within 2 hours of onset will reduce haematoma expansion compared with placebo.Sample size estimates A sample size of 180 patients(90 in each arm)would be required to detect an absolute difference in the primary outcome of 20%(placebo 39%vs treatment 19%)under a two-tailed significance level of 0.05.An adaptive sample size re-estimation based on the outcomes of 144 patients will allow a possible increase to a prespecified maximum of 326 patients.Intervention Participants will receive 1 g intravenous tranexamic acid over 10 min,followed by 1 g intravenous tranexamic acid over 8 hours;or matching placebo.Primary efficacy measure The primary efficacy measure is the proportion of patients with haematoma growth by 24±6 hours,defined as either≥33%relative increase or≥6 mL absolute increase in haematoma volume between baseline and follow-up CT scan.Discussion We describe the rationale and protocol of STOP-MSU,a phase Ⅱ trial of tranexamic acid in patients with ICH within 2 hours from onset,based in participating mobile stroke units and emergency departments.Nawaf Yassi Henry Zhao Leonid Churilov Bruce C V Campbell Teddy Wu Henry Ma Andrew Cheung Timothy Kleinig Helen Brown Philip Choi Jiann-Shing Jeng Annemarei Ranta Hao-Kuang Wang Geoffrey C Cloud Rohan Grimley Darshan Shah Neil Spratt Der-Yang Cho Karim Mahawish Lauren Sanders John Worthington Ben Clissold Atte Meretoja Vignan Yogendrakumar Mai Duy Ton Duc Phuc Dang Nguyen Thai My Phuong Huy-Thang Nguyen Chung Y Hsu Gagan Sharma Peter J Mitchell Bernard Yan Mark W Parsons Christopher Levi Geoffrey A Donnan Stephen M Davis 2022Stroke & Vascular Neurology2022,7,2:1
16Hydrogenbonding, crystallinity, and morphological properties of poly ( silicic acid)/waterbome polyurethane nanocomposites 显示文摘Ma Chen Chi M SU Hsun Yu Kuan Hsu Chiang 2005Journal of Polymer Science Part B : Polymer Physics2005,43,9:1
17Barbourin:a GpIIb-Iia-specific integrin antagonist from the venom of Sistrurusm Barbouri显示文摘Scarborough RM Rose JW Hsu MA 1991J Biol Chem1991,266,:1
18Fast and simple algorithms for recognizing chordal eomparabillty graphs and interval graphs 显示文摘Hsu W-L Ma T-H 1999SIAM Journal on Computing1999,28,3:1
19Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4 , CYP3A5 , and ABCB1 gene polymorphisms显示文摘Shih-Meng Tsai Chiou-Ya Lin Szu-Hsien Wu Linda Ann Hou Hsu Ma Li-Yu Tsai Ming-Feng Hou 2009Clinica Chimica Acta2009,,2:1
20p38 mitogen-activated protein kinase is involved in Fas ligand expression 显示文摘 Gavrilin MA Tsai MH 1999J Biol Chem1999,274,25:1
返回顶部 每页显示:
共6页 首页 上一页 第1页 下一页 末页 /6 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费